Dabigatran D4 | CAS 1618637-32-3 - Request Quote
Dabigatran D4
| SZ CAT No: | SZ-D012D02 |
| CAS No | 1618637-32-3 |
| Mol.F. | C25H21D4N7O3 |
| Mol.Wt. | 475.6 |
| Inv. Status | Synthesis on demand |
| Rel. CAS No | 2070015-06-2 (HCl salt) |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Dabigatran D4 is chemically 3-(2-(((4-Carbamimidoylphenyl-2,3,5,6-d4)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid. Dabigatran D4 is supplied with detailed characterization data compliant with regulatory guideline. Dabigatran D4 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Dabigatran.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 1618637-32-3
Purchase 1618637-32-3
Order 1618637-32-3
Enquire 1618637-32-3
price of 1618637-32-3
1618637-32-3 Supplier
1618637-32-3 Manufacturer
1618637-32-3 Exporter
buy high quality Dabigatran D4
Purchase Dabigatran D4
Dabigatran D4 suppliers
Dabigatran D4 manufacturers
Dabigatran D4 price
Order Dabigatran D4
Enquire Dabigatran D4
Dabigatran D4 cost
Dabigatran D4 Supplier
Dabigatran D4 Distributor
Dabigatran D4 for Method Validation
Dabigatran Reference Standard
Dabigatran D4 for ANDA Filing
Dabigatran D4 for Forced Degradation Studies
Dabigatran D4 Identification Standards
Dabigatran D4 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.


